Scarica l'app Stockscreener
0.3701
8.28%
-0.0334
Dopo l'orario di chiusura:
.36
-0.0101
-2.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
HC Wainwright Analysts Reduce Earnings Estimates for XFOR - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey
RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria
CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St
XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance
Layoff Tracker: Sensei to Cut 46% of Workforce, Close Research Site - BioSpace
X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ... - Yahoo Finance
X4 Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Stifel cuts X4 Pharmaceuticals target to $4, maintains Buy - Investing.com
X4 Pharmaceuticals: Promising Phase 2 Trial Results - TipRanks
X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) - Marketscreener.com
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
Xenon Reports Q3 2024 Financial Results and Business Update - The Manila Times
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Quantisnow
Great week for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) institutional investors after losing 18% over the previous year - Simply Wall St
X4 Pharmaceuticals Inc (XFOR) Has A Gold Mine On Its Hands - Stocks Register
Global Respiratory Disease Testing Market to Grow at a CAGR of ~4% by 2030 | DelveInsight - The Malaysian Reserve
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - GlobeNewswire
Ionis to present at upcoming investor conferences - Quantisnow
Glenmark Pharmaceuticals Ltd. Sees -4.19% Decline in Stock Price, Rated 'Hold' by MarketsMOJO - MarketsMojo
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewswire
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome - The Malaysian Reserve
Global Molecular Modeling Market to Hit USD 19.47 Billion by 2032, Driven by Demand for Drug Discovery Innovation and Advanced Computational Tools | Research by SNS Insider - 新浪香港
X4 Pharmaceuticals (XFOR) to Release Earnings on Wednesday - MarketBeat
Rigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition - Quantisnow
Vanguard Group Inc's Strategic Acquisition in X4 Pharmaceuticals Inc - GuruFocus.com
Top 50 Pharma: Oncology patent leaders 2024 - Drug Discovery & Development
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - Quantisnow
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - The Manila Times
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 - PR Newswire
Sun Pharma shares tumble 4% as US court blocks Leqselvi launch - The Economic Times
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - The Manila Times
9 Best Biotech Stocks Of November 2024 - Forbes
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - cnhinews.com
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - The Bakersfield Californian
Hypothyroidism Market to Expand by USD 789.8 Million (2024-2028) as New Drug Approvals Drive Revenue; Report Highlights AI's Role in Market TransformationTechnavio - The Malaysian Reserve
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - Business Wire
MIRA Pharma up 27% on ketamine analogue’s preclinical results for chemotherapy pain - Mugglehead
Acute Respiratory Distress Syndrome (ARDS) Market Statistics, Emerging Trends, Key Drivers And Forecast To ... - WhaTech
SEC Form 424B5 filed by Eledon Pharmaceuticals Inc. - Quantisnow
SG Americas Securities LLC Makes New Investment in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Block Deal Today: Pharma stock tanks 4% after stake sale worth Rs 3,000 crore by promoter - ET Now
Innovations in Pediatric Bladder Treatment: Shaping a Healthier Future As Discussed In New Market Research ... - WhaTech
Cyclic Heavy Menstrual Bleeding Market Advancements Highlighted by Research And Strategies For Expansion 20... - WhaTech
Acromegaly Market Innovations Investigated by Size, Share, Trends And Outlook Report 2024-2033 - WhaTech
Duchenne Muscular Dystrophy Therapeutics Market Trends, Growth Insights, and Forecasts 2033 - WhaTech
Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52% - Simply Wall St
Pituitary Dwarf Treatment Global Market Overview In Latest Study - WhaTech
Report Probes the Iron Deficiency Injectable Global Market Research - WhaTech
Basal Cell Carcinoma Treatment Market Analysis, Advancements, and Growth Potential - WhaTech
Alopecia Market Key Trends, Latest Insights, Future Trends And Forecast To 2033 - WhaTech
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):